In Demand
The recent explosive growth of antibody therapeutics has initiated a new era of targeted molecular therapy for the treatment of disease. Although therapeutic antibodies have proven to be immensely beneficial in treating a number of oncology and immunology indications, targeted antibody-based imaging agents remain very limited.

ImaginAb’s platform technology enables us to rapidly develop novel antibody-based imaging agents that can be used to advance development of therapeutic antibodies, diagnose disease, and transform the landscape of personalize medicine.

Our Impact on Drug Development: Companion Imaging Agents
Antibody-based diagnostic imaging agents promise to accelerate therapeutic antibody development at all stages in the pipeline from pre-clinical drug discovery through FDA marketing clearance:

• Pre-clinical evaluation of therapeutic antibody candidates to validate targeting and kinetics
• Generating critical in vivo data to facilitate go/no go decisions
• Patient selection & stratification for clinical trials
• Monitoring response to treatment and disease progression
• Facilitating FDA approval of antibody-based therapeutics
• Allowing for personalized medicine by phenotyping an individual’s expression of a target